IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob L who wrote (1566)	5/21/1998 11:35:00 AM
From: Roudy	Read Replies (1) of 1762

Hi Bob, Here are some numbers from a Piper Jaffray research report. Results from the Phase II trial of Rituxan treatment in combination with CHOP were orally presented at ASCO. This study included 33 patients who were diagnosed with intermdiate or high-grade NHL, and had no previous treatments. Of the 33 patients, 97% responded to the therapy, including 73% of patients experiencing a complete response and 24% a partial reponse. CHOP alone historically elicits an overall response rate of approximately 80% - 90%, and a complete response rate of 45% - 55% in this patient group. Don

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next